Clinical Trial Update: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

A randomized Phase 2/3 multi-center trial of SM-88 for metastatic pancreatic cancer was terminated, with results posted on 2024-11-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• SM-88

Snippet

Sponsor: Tyme, Inc | Conditions: Pancreatic Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-11-06